Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 9:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 51 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: n-3 control Clear all
Completed Phase 2 Interventional Results available

Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis

NCT01262898
View directory record Official record
Conditions
Gastroparesis
Interventions
GSK962040 (5 mg tablet), GSK962040 (25 mg tablet), GSK962040 (125 mg tablet), Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
9
States / cities
Concord, California • Indianapolis, Indiana • Chevy Chase, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Oct 19, 2026, 9:15 PM EDT
Terminated Phase 2 Interventional

A Randomized, Placebo-Controlled Trial of BMS-275291 Given Daily for 12 Months to Women With Stage 1c-IIIA Breast Cancer Receiving Adjuvant Chemotherapy and/or Hormonal Therapy

NCT00036621
View directory record Official record
Conditions
Breast Cancer
Interventions
BMS-275291
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
Chicago, Illinois • Indianapolis, Indiana • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2010 · Synced Oct 19, 2026, 9:15 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Effects of Omega-3 Docosapentaenoic Acid on Lipids and Other Risk Factors for Cardiovascular Disease

NCT04088240
View directory record Official record
Conditions
Elevated Triglycerides, Cardiovascular Risk Factor
Interventions
DPA enriched n-3, n-3 control, Placebo
Dietary Supplement
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 15, 2024 · Synced Oct 19, 2026, 9:15 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Fish Oil and Red Wine on Oxidative Stress Biomarkers

NCT00682318
View directory record Official record
Conditions
Healthy
Interventions
Fish Oil, Safflower Oil, Ethanol, Omega-3 polyunsaturated fatty acids, Omega-6 polyunsaturated fatty acid
Drug · Dietary Supplement
Lead sponsor
Carsten Skarke, MD
Other
Eligibility
21 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 19, 2026, 9:15 PM EDT
Terminated Phase 3 Interventional Results available

Palifermin in Lessening Oral Mucositis in Patients Undergoing Radiation Therapy and Chemotherapy for Locally Advanced Head and Neck Cancer

NCT00360971
View directory record Official record
Conditions
Head and Neck Cancer, Mucositis, Pain, Radiation Toxicity
Interventions
palifermin, cisplatin, placebo, neck dissection, radiation therapy
Biological · Drug · Other + 2 more
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
47
States / cities
Scottsdale, Arizona • Auburn, California • Burbank, California + 40 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2017 · Synced Oct 19, 2026, 9:15 PM EDT
Terminated Phase 2 Interventional Results available

Nutritional Adequacy Therapeutic Enhancement in the Critically Ill. The NUTRIATE Study

NCT01934192
View directory record Official record
Conditions
Gastroparesis
Interventions
GSK962040 50 mg, Metoclopramide 10 mg, Placebo NG, Placebo IV
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 85 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
Aurora, Colorado • Augusta, Georgia • Louisville, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Oct 19, 2026, 9:15 PM EDT
Recruiting Phase 2 Interventional

A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis

NCT06671054
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
AP1189, 40 mg, AP1189, 70 mg, AP1189, 100 mg, AP1189 matching placebo
Drug
Lead sponsor
SynAct Pharma Aps
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Cutler Bay, Florida • Miami, Florida • Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 19, 2026, 9:15 PM EDT
Completed Phase 2 Interventional Results available

Omega-3 Fatty Acids for Autism Treatment

NCT00786799
View directory record Official record
Conditions
Autism
Interventions
Omega-3 Fatty Acids
Dietary Supplement
Lead sponsor
University of California, San Francisco
Other
Eligibility
3 Years to 8 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2012 · Synced Oct 19, 2026, 9:15 PM EDT
Completed Phase 1 Interventional

rAAVrh74.MHCK7.DYSF.DV for Treatment of Dysferlinopathies

NCT02710500
View directory record Official record
Conditions
Dysferlinopathy
Interventions
rAAVrh74.MHCK7.DYSF.DV
Drug
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 19, 2026, 9:15 PM EDT
Completed Phase 3 Interventional

Comparison of Megestrol and/or Omega-3 Fatty Acid-Enriched Nutritional Supplement in Treating Patients With Cancer-Related Weight Loss and Lack of Appetite

NCT00031707
View directory record Official record
Conditions
Anorexia, Cachexia
Interventions
eicosapentaenoic acid, megestrol acetate, placebo
Dietary Supplement · Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
429 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
22
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 19, 2026, 9:15 PM EDT
Completed Phase 2 Interventional

A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C

NCT01482403
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Copegus, Pegasys, boceprevir, mericitabine, mericitabine placebo, boceprevir placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
7
States / cities
Littleton, Colorado • Chicago, Illinois • Shreveport, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2016 · Synced Oct 19, 2026, 9:15 PM EDT
Completed Not applicable Interventional

Double-Blind, Randomized, Placebo-Controlled Study of Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived) in ARC Patients

NCT00002012
View directory record Official record
Conditions
HIV Infections
Interventions
Interferon alfa-n3
Drug
Lead sponsor
Interferon Sciences
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 19, 2026, 9:15 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effect of Fish Oil Enriched In Omega-11 Fatty Acid On Lipoprotein Metabolism In Adults

NCT03043365
View directory record Official record
Conditions
Lipoprotein Metabolism, PCSK9, Proteomics
Interventions
control fish oil, LCMUFA-rich saury oil
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Oct 19, 2026, 9:15 PM EDT
Active, not recruiting Not applicable Interventional

Low-Fat Diet and Fish Oil in Men on Active Surveillance for Prostate Cancer

NCT02176902
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
Interventions
behavioral dietary intervention, omega-3 fatty acid, laboratory biomarker analysis
Behavioral · Dietary Supplement · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
50 Years to 80 Years · Male only
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 19, 2026, 9:15 PM EDT
Completed Phase 2 Interventional Results available

A Study To Investigate The Safety And Possible Clinical Benefit Of Multistem(r) In Patients With Moderate To Severe Ulcerative Colitis

NCT01240915
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
placebo, MultiStem low dose, MultiStem high dose
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
37
States / cities
San Francisco, California • Lafayette, Colorado • Lakewood, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2016 · Synced Oct 19, 2026, 9:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Expanded Game Squad for Neurodiverse Youth

NCT03665415
View directory record Official record
Conditions
Physical Activity, Mental Health Issue (E.G., Depression, Psychosis, Personality Disorder, Substance Abuse), Health Behavior, Developmental Disorder
Interventions
NDGameSquad
Behavioral
Lead sponsor
Merrimack College
Other
Eligibility
11 Years to 18 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts • Marblehead, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Oct 19, 2026, 9:15 PM EDT
Completed Not applicable Interventional

Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole

NCT01478477
View directory record Official record
Conditions
Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
omega-3 fatty acid supplement, Placebo, Clinical assessments, Assessment of therapy complications, Magnetic Resonance Imaging, Correlative/special studies
Dietary Supplement · Other · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Oct 19, 2026, 9:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Obesity and Caries in Young South Asian Children: A Common Risk Factor Approach

NCT03077425
View directory record Official record
Conditions
Pediatric Obesity, Early Childhood Caries
Interventions
Enhanced Usual Care (EUC), Intervention
Behavioral
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
3 Months to 2 Years
Enrollment
380 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
8
States / cities
East Windsor, New Jersey • New Brunswick, New Jersey • Jamaica, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Oct 19, 2026, 9:15 PM EDT
Completed Not applicable Interventional

Effect of a Component of Fish Oil on Exercise-Induced Bronchoconstriction and Airway Inflammation in Asthma

NCT01504646
View directory record Official record
Conditions
Asthma, Exercise-Induced Bronchoconstriction
Interventions
Lyprinol, Placebo (Olive Oil)
Dietary Supplement
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 30 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Oct 19, 2026, 9:15 PM EDT
Terminated Not applicable Interventional

n-3 Polyunsaturated Fatty Acids to Prevent and Treat Diabetic Neuropathy

NCT05145452
View directory record Official record
Conditions
Diabetic Neuropathies
Interventions
Fish-oil derived n-3 polyunsaturated fatty acids
Dietary Supplement
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
55 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 19, 2026, 9:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Side Effects of the mGlu5 Antagonist Fenobam in Adult Healthy Volunteers

NCT01806415
View directory record Official record
Conditions
Healthy
Interventions
Fenobam, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Oct 19, 2026, 9:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 TP-271 Oral PK Single Ascending Dose Study

NCT03024034
View directory record Official record
Conditions
Bacterial Infections
Interventions
TP-271
Drug
Lead sponsor
Tetraphase Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Oct 19, 2026, 9:15 PM EDT
Completed Not applicable Interventional

Omega-3 Fatty Acid in Treating Pain in Patients With Breast or Ovarian Cancer Receiving Paclitaxel

NCT01821833
View directory record Official record
Conditions
Breast Cancer, Ovarian Neoplasm, Pain
Interventions
Omega-3 fatty acid, Placebo, Paclitaxel
Dietary Supplement · Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Oct 19, 2026, 9:15 PM EDT
Completed Phase 2 Interventional Results available

Study Of Safety And Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus

NCT01336738
View directory record Official record
Conditions
Diabetes, Type 2
Interventions
Placebo, 150 mg PF-04991532, 450 mg PF-04991532, 750 mg PF-04991532, Sitagliptin 100 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
28
States / cities
Jonesboro, Arkansas • Los Angeles, California • Palm Springs, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2013 · Synced Oct 19, 2026, 9:15 PM EDT